Compare MTH & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTH | GRFS |
|---|---|---|
| Founded | 1985 | 1940 |
| Country | United States | Spain |
| Employees | N/A | 25247 |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 5.5B |
| IPO Year | 1997 | N/A |
| Metric | MTH | GRFS |
|---|---|---|
| Price | $65.54 | $8.72 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 8 | 2 |
| Target Price | ★ $83.38 | $10.15 |
| AVG Volume (30 Days) | ★ 869.1K | 683.5K |
| Earning Date | 04-22-2026 | 07-28-2022 |
| Dividend Yield | ★ 2.88% | 1.68% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.35 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $4.69 |
| Revenue Next Year | $9.78 | $6.49 |
| P/E Ratio | ★ $10.50 | $18.67 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $58.03 | $6.86 |
| 52 Week High | $84.54 | $11.14 |
| Indicator | MTH | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 51.71 | 60.96 |
| Support Level | $64.80 | $8.66 |
| Resistance Level | $75.71 | $8.94 |
| Average True Range (ATR) | 1.84 | 0.20 |
| MACD | 0.96 | 0.12 |
| Stochastic Oscillator | 76.60 | 97.67 |
Meritage Homes Corp is engaged as a designer and builder of single-family attached and detached homes. It has operations in three regions: West, Central, and East, comprising twelve states: Arizona, California, Colorado, Utah, Tennessee, Texas, Alabama, Florida, Georgia, Mississippi, North Carolina, and South Carolina. The company operates with two principal business segments: homebuilding and financial services. The homebuilding segments are engaged in the business of acquiring and developing land, constructing homes, marketing and selling those homes, and providing warranty and customer services, and the financial services segment offers title and escrow, mortgage, and insurance services. The company generates key revenue from the Homebuilding segment.
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.